There are no milestone payments pursuant to FDA approval, but MNTA receives a roughly 45% share of Lovenox net profits as long as there is only one generic on the market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”